Convalecent - Hyperimmune Plasma Use and Immunological Charachteristics in the Covid-19 Pandemic: A Preliminary Experience of a Single Center in Italy as Fast Available Therapy Model in New Virus Pandemic
DOI:
https://doi.org/10.14738/bjhr.1106.18040Keywords:
Convalescent - Hyperimmune Plasma, Blood Transfusion, COVID-19, Pandemic, SARS-CoV-2 Corona VirusAbstract
Objectives: Hyperimmune - convalescent plasma transfusion appears to be a great resource in the current SARS-CoV-2 coronavirus pandemic and seems to be one of the few effective treatment modality available. However, its efficacy is variable and dependent on antibody/plasma volume concentration. Methods & Results: This single center analysis from a forefront COVID-19 Italian hospital in 43 convalescent plasma donors demonstrated that this variability in neutralizing antibody (NAB) levels is related to the harvesting period after SARS-CoV-2 recovery and interestingly, on blood group type. Specifically, the optimal plasmaferesis time point was approximately two weeks post test negativation with a significant drop in NAB plasma levels (112±102 vs 60±26.9, p=0.003) observed at 30 days. In contrast, no correlation between NAB and IgG plasma levels was observed over time (r=0.48.). Subgroup analyses demonstrated that NAB levels where higher in male (115.1±110.7, p=0.0001) and in blood group AB (200±138.6, p=0.036) donors while group A patients (81.2±82.7, p=0.062) had the lower levels of NAB concentration. Conclusion: This analysis demonstrated that male patient with a AB blood group plasma which was donated within three weeks of convalescence contains the highest therapeutic levels of antibodies and these patients should be actively recruited to become donors.
References
Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, Franchini M, COVID-19 Plasma Task Force. Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020; 105(12): 2834-40. https://doi:10.3324/haematol.2020.261784.
Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, Zhang Z, Liu L, Liu T, Liu Y, He Y, Sun B, Wei M, Yang G, Wang X, Zhang L, Zhou X, Xing M, Wang PG, Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility, Clinical Infectious Diseases, 2020; ciaa1150. https://doi:10.1093/cid/ciaa1150. 315
Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020; 11: 5761. https://doi: 10.1038/s41467-020-19623-x.
Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, Ng MH, Sung JJ, Wong RS, ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 2005; 293: 1450-51. https://doi:10.1001/jama.293.12.1450-c.
23andMe. (2020, September 4th) 23andMe Finds Evidence that Blood Type Plays a Role in COVID-19. 23andMe Blog. Available at: https://blog.23andme.com/23andmeresearch/blood-type-and-COVID-19/(Accessed on: 11 November 2020)
Severe Covid-19 GWAS Group, Genome wide association study of severe COVID-19 with respiratory failure. N Engl J Med. 2020; 383(16): 1522-34. https://doi: 10.1056/NEJMoa2020283.
Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020; 190(1): 24-27. https://doi: 10.1111/bjh.16797
Gérard C, Maggipinto G, Minon JM. COVID-19 and ABO blood group: another viewpoint. Br J Haematol. 2020; 190(2): e93-e94. https://doi: 10.1111/bjh.16884
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. 2020; 52(6): 910-941. https://doi:10.1016/j.immuni.2020.05.002.
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95(9):1888-97. https://doi:10.1016/j.mayocp.2020.06.028.
European Commission, Directorate-General for Health and Food Safety, Directorate B - Health systems, medical products and innovation. (2020). An EU programme of COVID-19 convalescent plasma collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use. Available at: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf (Accessed on: 6 January 2021] TABLES
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Philippe P. Caimmi, Gennaro Mascaro
This work is licensed under a Creative Commons Attribution 4.0 International License.
